RCUSNYSEPharmaceutical PreparationsFiscal year ends December 31
Arcus Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$22.14+0.02 (+0.09%)
Close on Oct 19, 2026
- Market cap
- $2.79B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2015 to 2025
Operating margin
-156.3%+2.7 pts over 5 years
Net margin
-142.9%+14.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -4.3% | +30.2% | +25.9% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 162.1% | -36.9% | -63.3% | |
| Return on assets | – | -25.2% | -30.8% | |
| Current ratio | – | 6.05 | 4.36 | |
| Interest coverage | – | – | -48.3× | |
| Capex to revenue | – | 3.8% | 0.8% | |
| Diluted shares | 1M | 55M | 107M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Arcus Biosciences generated $1.65B from operations and spent $64.00M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$1.65B
Used
$64.00M
Capital expenditure$64.00M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-142.9%
×Asset turnover0.22×
×Equity multiplier2.05×
=Return on equity, FY2025-63.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -142.9% | 0.22× | 2.05× | -63.3% |
| FY2024 | -109.7% | 0.23× | 2.37× | -59.8% |
| FY2023 | -262.4% | 0.10× | 2.18× | -54.9% |
| FY2022 | -238.4% | 0.08× | 1.96× | -35.6% |
| FY2021 | 13.8% | 0.32× | 1.76× | 7.9% |
| FY2020 | -157.7% | 0.16× | 1.46× | -36.9% |
| FY2019 | -564.7% | 0.06× | 1.20× | -42.5% |
| FY2018 | -593.7% | 0.04× | 2.86× | -61.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
0of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$353.00M
- Cash generatingOperating cash flow above zero-$482.00M
- Return on assets improvedROA up on the prior year-25.8% → -30.7%
- Earnings backed by cashOperating cash flow above net income-$482.00M vs -$353.00M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose4.50 → 4.36
- No dilutionShare count did not rise90M → 107M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.24 → 0.21